CLEC10A and neoplasm: For example, in TRACERx, a large prospective observational cohort study on non-small cell lung cancer, the env-glycoproteins of HERV-K(HML-2) (HGNC: 13915), were demonstrated a dominant anti-tumor antibody target, significantly contributing to amplified B cell responses by immune checkpoint inhibitor, thus enhancing anti-tumor immunity(Ng et al., 2023).